Two-shots-on-goal deal gives Array best odds for $685M milestones in Genentech pact
This article was originally published in Scrip
Executive Summary
Array BioPharma CEO Robert E Conway said a new deal with long-time partner Genentech to develop Checkpoint kinase-1 (ChK-1) molecules is not only garnering his firm $28 million up front, but with a ChK-1 from both companies in the game, the "two-shots-on-goal" pact gives his biotech the best odds of achieving the $685 million in milestones on the table.